Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy

NCT ID: NCT01090531

Last Updated: 2020-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational long-term follow-up study will evaluate demographic, clinical, histological, biochemical, and virological parameters of patients with chronic hepatitis B and low viremia who do not require antiviral therapy according to current guidelines. Liver stiffness values as detected by FibroScan and ARFI will also be collected if available. All data will be collected at yearly intervals (minimum). Patients included in the study are followed for up to 10 years. The target sample size is \<1000.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patient, age 18-79
* chronic hepatitis B
* HBV-DNA \< 100.000 IU/ml
* ALT ≤2 x ULN
* recent liver histology and/or FibroScan measurement
* willingness to sign informed consent

Exclusion Criteria

* current or past antiviral therapy for hepatitis B
* chronic hepatitis B in immune tolerance phase (HBeAg positive, high viral load)
* co-infection with HIV, HCV
* malignant disease
* HCC or other liver tumor
Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johann Wolfgang Goethe University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Georg Dultz

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christoph Sarrazin, MD

Role: PRINCIPAL_INVESTIGATOR

Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charité Berlin-Campus Virchow-Klinikum

Berlin, , Germany

Site Status

Klinikum der J. W. Goethe-Universität

Frankfurt, , Germany

Site Status

Institut für Interdisziplinäre Medizin

Hamburg, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Gastroenterologische Gemeinschaftspraxis Herne

Herne, , Germany

Site Status

Gastroenterologische Gemeinschaftspraxis Kiel

Kiel, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JWGUHMED1-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.